The next generation of antibody–drug conjugates

The article published in Nature Medicine on August 3, 2026, discusses the next generation of antibody-drug conjugates (ADCs). The authors outline strategies to maximize the impact of these drugs. A key aspect is integrating multiple chemistry advances directly into the drug constructs. Simultaneously, it is necessary to develop new infrastructures and tools. These tools aim to accelerate and de-risk the preclinical and early clinical development of ADCs. The goal is a more efficient and safer introduction of these innovative medicines into practice.